Lethyl

Quick links to important sections

Lethyl

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lethyl

Property Description
Active ingredient Phenobarbital (or Phenobarbital sodium)
Forms Tablet, Elixir, Injection
Pharmacological class Barbiturate, CNS Depressant
General purpose Control of excessive electrical activity
Origin Synthetic, Barbituric Acid Derivative

Lethyl: Definition and Pharmacological Identity

Lethyl is a pharmaceutical preparation containing the single active ingredient, Phenobarbital (C₁₂H₁₂N₂O₃), which is classified as a synthetic barbiturate derivative. This compound is structurally defined as 5-Ethyl-5-phenylbarbituric acid and belongs to the barbiturate pharmacological class. Lethyl is recognized as a nonselective Central Nervous System (CNS) Depressant and is categorized as a long-acting agent. Phenobarbital is an anticonvulsant and is included on lists of essential medicines.

The preparation is a single-ingredient product; the active substance is Phenobarbital, which is also available as the soluble salt, Phenobarbital sodium, primarily used for formulations intended for injection.

Available Forms and General Therapeutic Purpose

Lethyl is provided in several distinctive dosage forms, including the oral tablet, the elixir (a hydroalcoholic solution), and the injection (aqueous solution/sterile powder), accommodating administration via the oral and parenteral routes. The elixir form enables use in patient groups, such as children, who may require a liquid formulation for ease of administration.

Lethyl's function as a long-acting depressant allows it to raise the brain's threshold for abnormal electrical discharges. This mechanism underpins its purpose in stabilizing the central nervous system, which contributes to the general management of seizure disorders and the induction of sedation.


Regulatory References

  1. WHO Model List of Essential Medicines

What side effects are possible with Lethyl?

The safety profile of Lethyl (Phenobarbital) is defined by officially documented adverse reactions classified by frequency and body system, strictly based on regulatory labeling.

Adverse Reaction Classifications

Adverse reactions are organized by System-Organ Classes (SOCs). Effects on the Nervous System are the most frequently reported, including common effects such as somnolence, residual sedation, lethargy, vertigo, and ataxia. Less common effects across various systems include nausea, vomiting, constipation, and headache. The drug's classification as a long-acting CNS depressant is central to its safety characteristics.

System-Organ Class Common Adverse Reactions
Nervous System Somnolence, Sedation, Lethargy, Ataxia, Vertigo
Gastrointestinal Nausea, Vomiting, Constipation
Skin Hypersensitivity reactions (Rashes)

Serious Adverse Reactions and Safety Patterns

Regulatory documents list several Serious Adverse Reactions (SARs) that are rare but clinically critical. These include Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Suicidal ideation and behavior have also been reported with anti-epileptic agents, including Lethyl. Serious effects on the circulatory and respiratory systems, such as circulatory collapse and severe respiratory depression, are noted, particularly with rapid intravenous administration.

Long-term use is associated with risks of physical and psychological dependence, requiring careful management of discontinuation to prevent severe withdrawal syndrome. Chronic exposure may also lead to changes in metabolism, including decreased bone mineral density and risk of osteomalacia.

Population-Specific Safety Considerations

Specific safety statements exist for vulnerable populations. In both children and older adults, the medicine may paradoxically cause excitement, restlessness, or confusion instead of sedation. Use during pregnancy is associated with a risk of fetal harm and potential neonatal withdrawal syndrome. The drug is contraindicated in patients with acute intermittent porphyria, known barbiturate hypersensitivity, and severe hepatic or renal impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

Lethyl is a prescription sedative-hypnotic agent, and taking more than the prescribed dose, whether accidentally or intentionally, can lead to an overdose. An overdose of Lethyl is a medical emergency that requires immediate professional attention as it can result in severe central nervous system and respiratory depression, which may be fatal.

Signs and Symptoms of Overdose

Symptoms of a Lethyl overdose can range from mild intoxication to life-threatening conditions. Immediate symptoms may include:

  • Central Nervous System Effects: Severe drowsiness, profound confusion, loss of coordination (ataxia), slurred speech, stupor, and ultimately, coma.
  • Respiratory and Cardiovascular Effects: Slowed, shallow, or stopped breathing (respiratory depression), decreased heart rate, and very low blood pressure (profound hypotension).
  • Other Physical Signs: Cold, clammy skin, and diminished or absent reflexes.

When to Seek Help

Call your local emergency services immediately if you or someone else has taken too much Lethyl or is exhibiting any signs of an overdose. Do not wait for symptoms to worsen. Be prepared to provide the emergency operator with information about the substance taken, the approximate amount, and when it was ingested. Treatment for an overdose typically involves supportive care, such as maintaining an open airway, providing mechanical ventilation, and managing blood pressure.

Therapeutic Uses of Lethyl

What Lethyl Treats: Main Uses and Benefits

Lethyl is commonly used in situations involving symptoms of increased neurological or muscular activity, applied across domains where additional symptomatic support is needed in situations involving heightened physiological activity. The medication's primary benefit is to help reduce the intensity and impact of distressing manifestations, contributing to improved comfort and stability during acute or chronic symptomatic periods.

The primary indications for Lethyl include managing recurrent or chronic seizure manifestations of epilepsy, supporting symptom stabilization during acute detoxification from alcohol and sedatives, and providing pronounced sedative support in cases of severe anxiety-tension or pathological restlessness.

“The therapeutic benefit supports neurological stability, which may assist in managing recurrent episodes and easing distress during acute symptomatic phases.”

Quick Fact: Relief for Hyperexcitability

Lethyl is considered relevant in acute scenarios for helping to manage prolonged and severe convulsive episodes. It is applied during phases when symptoms become more noticeable, offering symptomatic relief that helps patients cope more steadily with symptom fluctuations, and may assist with maintaining functional stability.

Eligibility and Restrictions for Use

Who Can and Cannot Use Lethyl?

The eligibility for using Lethyl (Phenobarbital) is defined by official regulatory documents based on patient characteristics, organ function, and specific medical conditions. Use is contraindicated and strictly prohibited in patients with hypersensitivity to barbiturates or any component of the formulation, severe respiratory depression, Acute Intermittent Porphyria (manifest or latent), and severe impairment of liver or renal function.


Restrictions for Specific Populations

Population Group Official Regulatory Status
Older Adults (Geriatric) Use requires caution; often necessitates lower doses due to risk of confusion and paradoxical excitement.
Pediatric Patients Approved for use, but use is contraindicated in hyperkinetic children and may be associated with cognitive deficits.
Pregnancy Restricted Use (Pregnancy Category D); permitted only when the medical benefit significantly outweighs the potential risk to the fetus.
Breastfeeding Women Caution is advised, as the medicine is excreted into breast milk and may cause neonatal sedation or poor weight gain.

Eligibility is also restricted for patients with a history of drug abuse/alcoholism and should be avoided in uncontrolled pain due to the risk of paradoxical effects.

What should I know about interactions with other medicines?

Lethyl Interactions with other medicines and products

Lethyl (simvastatin) is subject to significant restrictions when taken with other medicines and products due to drug-drug interactions, which can increase its concentration in the bloodstream. Concomitant use with specific drugs, mainly strong CYP3A4 inhibitors, is contraindicated (must be avoided). These agents include certain macrolide antibiotics (e.g., clarithromycin, erythromycin), azole antifungals (e.g., itraconazole, ketoconazole), and HIV protease inhibitors. Co-administration is also contraindicated with gemfibrozil, cyclosporine, and danazol.

Specific dosage restrictions apply when Lethyl is used with other medications that modestly inhibit its metabolism. The Lethyl dose must not exceed 10 mg daily when co-administered with verapamil or diltiazem. The maximum Lethyl dose is restricted to 20 mg daily when co-administered with amiodarone, amlodipine, or ranolazine.

Patients should also avoid consuming large quantities of grapefruit juice (more than one quart daily) as it can increase the systemic exposure of Lethyl. Products that induce the CYP3A4 enzyme may reduce Lethyl's effectiveness, necessitating careful monitoring. These constraints are established in regulatory documents to manage the risk associated with elevated Lethyl exposure.

Mechanism of Action

Modulation of GABA A Receptor Signaling

Lethyl's primary mechanism of action involves interaction within the domain of receptor-mediated signaling, specifically by acting as a positive allosteric modulator of the GABA A receptor complex. This effect enhances the inhibitory actions of the neurotransmitter gamma-aminobutyric acid (GABA). This sequence results in a prolonged influx of chloride ions ( Cl^-) into the postsynaptic neuron.


Neuronal Membrane Hyperpolarization

The heightened Cl^- conductance triggered by Lethyl leads to hyperpolarization of the neuronal cell membrane, increasing the difference in charge across the membrane. This shift raises the threshold required for action potential generation, consequently reducing the cell's probability of firing. This mechanism contributes to a reduction in the rate of high-frequency electrical signal propagation within neural pathways.


Systemic Reduction of Neuronal Activity

Lethyl also influences various neural processes by engaging secondary mechanisms, including the modulation of certain excitatory glutamate receptors. The resulting combination of enhanced inhibitory signaling and reduced excitatory signaling modifies early molecular steps, resulting in an overall decrease in central nervous system (CNS) neuronal activity. This effect systematically modulates the physiological firing patterns across various neural systems.

Dosage and Administration Information

How to Use Lethyl

Lethyl (Phenobarbital) is administered according to protocols that standardize its use based on the intended purpose and dosage form. The medication is available for oral use as tablets or an elixir, and as an injection (Phenobarbital sodium) for parenteral administration via the intravenous (IV) or intramuscular (IM) routes.

Administration and Dosing

The established dosing regimens vary based on the context of use. For adult anticonvulsant maintenance, the dosage typically ranges from 50 mg to 100 mg, taken two or three times daily, or as a single daily dose of 100 mg to 300 mg. Due to the drug's long half-life, a single daily dose is often prescribed at bedtime to maintain consistent levels.

Context of Use Administration Principles
IV Administration Injection is administered slowly, not exceeding 60 mg/minute in adults, often requiring prior dilution.
Timing & Food Lethyl may be taken with or without food.
Population Adjustment Dose reduction is recommended for older adults and patients with hepatic or renal impairment.

Duration and Cessation

Achieving the full anticonvulsant effect typically requires two to three weeks of continuous therapy to reach stable plasma concentrations. For short-term use, such as the hypnotic application, the duration is limited, often specified as not exceeding two weeks. Discontinuation of Lethyl is subject to a specific protocol: the dose must be gradually reduced over a period (e.g., one week) to prevent acute withdrawal manifestations. This structured approach governs the drug's administration.


Recent Clinical Evidence

Research evidence / Overview of studies for Lethyl


Evidence for Chronic Seizure Disorders (Epilepsy)

Research has explored the use of Lethyl in studies examining chronic seizure disorders, which are conditions characterized by fluctuating or episodic manifestations. This research includes systematic reviews and older randomized controlled trials (RCTs), which were applied in studies examining patient-reported experiences related to seizure monitoring and overall daily functioning. These studies were conducted across both adult and pediatric populations diagnosed with focal onset seizures and generalized seizures. Studies focused on measuring the proportion of participants who were seizure-free for defined time intervals and the monitoring of changes in overall seizure frequency.

Findings describe patterns observed in the studies related to these primary measures. However, research so far indicates that the results apply only to the populations studied, and evidence quality varies across the existing body of work. Comparative evidence is limited against certain other treatments, and the follow-up durations were limited in some key trials, meaning long-term effects are not fully established.


Evidence for Acute Neurological Stabilization

Lethyl was also evaluated in research contexts involving fluctuating or unstable symptoms, specifically in conditions associated with acute or disruptive episodes, such as neonatal seizures and severe alcohol withdrawal syndrome (AWS). Research examined outcomes describing episodic or acute changes and explored short-term symptom changes.

Research describes patterns related to the measurement of seizure activity cessation in newborns, and outcomes included monitoring for the use of additional treatments in certain neonates. Evidence derived from settings with varying symptom burdens for severe AWS included studies that monitored requirements for additional sedative doses and ICU stay duration. Data are still emerging for some acute indications, and certainty remains low regarding the consistency of extended outcomes across different study settings.


Research Gaps and Areas of Uncertainty

This section synthesizes the main limitations noted across the research. Evidence quality varies across studies, especially older ones, and follow-up durations were limited in many key acute management studies. The evidence is limited in providing consistent insight into long-term outcomes related to specific neurological and behavioral health outcomes, and findings were mixed or inconsistent in the research exploring long-term neurodevelopment in infants.

Comparative evidence is limited against certain other treatments. These research limitations indicate that data remain limited in some areas. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes, which highlights what is known and what is still uncertain.

Key Studies & References

  1. Phenobarbital Sodium Injection: Prescribing Information (FDA DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Lethyl (FAQ)


Q: How quickly does Lethyl usually start to work?

According to official product information, Lethyl's onset of action when taken by mouth is typically within 30 minutes. However, the time it takes to reach maximum concentration in the blood, and thus its full effect, is documented as 8 to 12 hours. The initial effect with intravenous administration is described as being noticeable within 5 minutes.


Q: What is the time period Lethyl stays in your body?

Lethyl is classified as a long-acting medication. Official documents show that its elimination half-life—the time it takes for half the dose to leave the body—ranges from approximately 53 to 118 hours (about two to five days). Due to this long half-life, the medication remains in the system for an extended period.


Q: Is Lethyl considered a long-term medication?

Lethyl has different uses that determine the recommended duration. For the treatment of chronic seizure disorders (anticonvulsant use), it is intended for chronic management. However, when used for short-term sedation (hypnotic use), the duration is limited and often recommended for no more than two weeks.


Q: Is Lethyl known to be safe during pregnancy?

Regulatory documents officially assign Lethyl a Pregnancy Category D. This classification indicates that there is official evidence of human fetal risk. The drug is reserved for use during pregnancy only when the prescribing healthcare provider determines the potential benefit is judged to outweigh the potential risk to the fetus.


Q: Is it normal to feel a bit tired when beginning Lethyl treatment?

Somnolence (drowsiness) and lethargy (lack of energy) are among the most common adverse reactions reported in official documents. These are effects on the nervous system that are estimated to occur in a small percentage of patients.


Q: What if I experience mild nausea after starting Lethyl?

Nausea and vomiting are listed among the possible gastrointestinal adverse reactions in official prescribing information. These effects are estimated to occur in less than 1 out of 100 patients. This effect is noted in the full safety information section, which provides a complete list of potential adverse effects.


Q: Is Lethyl usually taken every day?

For its use in chronic seizure disorders, Lethyl is typically taken daily to maintain stable levels. The drug's long half-life often allows for a single daily dose, but the exact daily schedule is determined by the prescriber.


Q: Do you have to take Lethyl with food?

Official patient information states that Lethyl may be taken with or without food. This statement describes the condition of use, not a specific requirement for timing around meals.


Q: Can Lethyl be used by people with a history of heart issues?

Regulatory documents advise that Lethyl should be administered with caution to patients with a history of low blood pressure (hypotension) or existing cardiovascular disease. This is due to the potential for severe effects on the circulatory system, which are noted in safety warnings.


Q: Are there any common foods or drinks that should be avoided when taking Lethyl?

Official regulatory warnings advise against the use of alcohol when taking Lethyl. The warning notes that using alcohol with Lethyl may result in additive depressant effects on the central nervous system.


Q: Why do some people say Lethyl is similar to [Similar Drug Name]?

Lethyl’s active ingredient belongs to the barbiturate pharmacological class. This is a category of drugs that primarily acts as a Central Nervous System (CNS) Depressant, which means it shares a similar fundamental mechanism with other medications in this class used for seizure management and sedation.


Q: Does Lethyl have a warning about driving or operating machinery?

Yes, official patient warnings state that Lethyl may impair thinking or reactions. Regulatory documents state that caution is advised regarding activities that require full mental alertness, such as driving or operating machinery.


Q: Is Lethyl a controlled substance?

Yes, the active ingredient in Lethyl (phenobarbital) is officially classified as a Schedule IV controlled substance under federal law. This classification is used for substances with accepted medical use that also carry a risk of dependence.


Q: Is it true that Lethyl can cause difficulty sleeping?

Although Lethyl is often used to cause sedation, official adverse reaction reports also list insomnia (difficulty sleeping) and nightmares as nervous system effects. These are estimated to occur in less than 1 out of 100 patients.


Q: Can older adults typically use Lethyl?

Use in older adults is permitted but requires reduced dosage because these patients may be more sensitive to the drug's effects. Official information also notes that the medicine may paradoxically cause excitement, restlessness, or confusion in this population.


Q: Why does the packaging list so many potential interactions?

Official documentation explains that Lethyl's active ingredient is a potent inducer of certain cytochrome P450 enzymes in the liver. Because Lethyl speeds up the breakdown of many co-administered drugs, a large number of interaction warnings are necessary to manage the risk of reduced effectiveness of those other medications.


Q: Are there any mental health side effects listed for Lethyl?

Yes, official documents list effects on mental health. This includes a Boxed Warning about suicidal ideation and behavior associated with anti-epileptic agents. Other reported effects include emotional disturbances, anxiety, and psychiatric disturbance.


Q: Does Lethyl have any specific requirements for monitoring by a healthcare provider?

Official documents recommend therapeutic drug monitoring (TDM). This involves checking the serum (blood) concentrations of Lethyl, often 3 to 4 weeks after the maintenance dose has been achieved, to ensure consistent and appropriate levels.


Q: Is Lethyl a type of antidepressant?

No. The active ingredient in Lethyl, phenobarbital, is classified by regulatory bodies as a barbiturate and a Central Nervous System (CNS) Depressant. It is not classified as an antidepressant.


Q: What is the risk of having a serious interaction with Lethyl?

The risk is considered serious when Lethyl is taken with specific medications that strongly affect certain liver enzymes. Coadministration with these specific drugs is generally contraindicated by official documents.


Q: What are the chances of an allergic reaction to Lethyl?

Official documents list allergic reactions, including localized swelling and rashes, as potential adverse effects. Rare but fatal Severe Cutaneous Adverse Reactions (SCARs) are also listed. These events are noted in the safety information, but a precise frequency for all allergic reactions is not given in the general labeling.


Q: What is the main concern doctors have when prescribing Lethyl?

Official warnings focus heavily on several critical safety considerations for prescribers. These include the risk of dependence and withdrawal, potential for severe respiratory depression, and the possibility of serious dermatologic reactions like Stevens-Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN).


Q: Is it a common issue for Lethyl to cause dizziness?

Dizziness (vertigo) is listed among the nervous system side effects in official safety documents. It is estimated to occur in less than 1 out of 100 patients, indicating it is not classified as a common issue.

How should Lethyl be stored and disposed of?

How to Store and Dispose of Lethyl

Official labeling defines strict storage and disposal requirements for Lethyl (Phenobarbital), a Schedule IV controlled substance.


Storage Conditions

  • Temperature: Store at controlled room temperature, specifically 20° to 25°C (68° to 77°F).
  • Protection: The product must be protected from light and moisture and kept in a tightly closed, light-resistant container.
  • Security: Due to the risk of misuse, Lethyl must be stored in a safe, locked place and kept strictly out of the reach of children.

Disposal Instructions

  • Primary Method: Dispose of unused or expired product primarily through a drug take-back program or mail-back service.
  • Environmental Rule: The product must not be allowed to enter sewers or surface water during disposal. Alternative disposal in household trash requires mixing the drug with an undesirable substance before sealing and discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lethyl found in:

A-Z Index: